Clinical Trials Browser

Terminated × INDUSTRY × catumaxomab × Clear all

NCT01320020 2013-07-02

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Phase 1 Terminated

Carcinoma, Neoplasms